A sleek monitoring equipment, that uses remote monitoring technology which was test-run and subsequently used during the COVID-19 pandemic to protect health patients through detecting irregularities in their heart would now be made available to residents of the United Kingdom, North East and Columbria.
The new KardiaMobile 6L portable ECG device, by the Tees, Esk and Wear Valleys Foundation Trust (TEWV) was used during the pandemic to help monitor patients isolating in their homes on information about their heart rate and rhythm via the electrocardiogram method.
The National Health Service User Experience (NHSX), a United Kingdom Government unit charged with the mandate for setting national policy and developing best practice for National Health Service (NHS) technology, digital and data, including data sharing and transparency had been actively monitoring the research work and supporting it with the deployment of remote monitoring technology across the UK, with other programs in the North East and North Cumbria.
Patients suffering from schizophrenia, and who use antipsychotic medications will need to have regular ECGs (Electrocardiogram) to monitor the heart flow and rhythm as a result of their risk of having arrhythmias that are responsible for convulsions, dizziness. These patients will normally have to undergo ECGs in a configuration that requires a large twelve-lead ECG to be connected to the patient, with ten separate leads attached to their chest, arms, and legs. It makes use of a reading device, the KardiaMobile 6l which will read the frequency and rhythm of the heart in 30 seconds.
The Chief Digital Officer if the National Health Service User Experience (NHSX), Tara Donnelly, while analysing the new technology in a statement said:
“Through the pandemic at NHSX, we have been helping scale new technology that allows clinicians to monitor and assess patients’ conditions remotely. As part of our Innovation Collaborative, NHSX is delighted to be working in partnership with innovators and teams that are transforming care for thousands of people,”
The Tees, Esk and Wear Valleys (TEWV) team obtained at least 30 devices that were then used to monitor the impact of the antipsychotic drugs on the patient’s heart condition in their homes in an initial three-month period.
In the space of that time, over 300 patients were closely monitored, this saved an average of 17.5 minutes per ECG with very gratifying feedback from staff and patients who preferred the new technology to the conventional ECG which is less comfortable to the patient, with the analysis and response to findings slower than the new method. The old method has to involve a large 12-lead machine that can be time consuming and a paper-based method that requires administering by trained professionals
According to NHSX Chief Digital Officer, Donnelly: “More patients in the North East and North Cumbria requiring antipsychotic medication will now have their ECG recorded in their own homes and assessed remotely by clinicians that ensure their medication can be safely administered,”
We can then say kudos to the team and NHSX. There is indeed a brighter future for medical science.